4.3 Article

Comparative Effectiveness of Transcutaneous Auricular Vagus Nerve Stimulation vs Citalopram for Major Depressive Disorder: A Randomized Trial

Journal

NEUROMODULATION
Volume 25, Issue 3, Pages 450-460

Publisher

ELSEVIER
DOI: 10.1016/j.neurom.2021.10.021

Keywords

Citalopram; depression; glutamate; major depressive disorder; transcutaneous auricular vagus nerve stimulation

Funding

  1. CACMS Innovation Fund [CI2021A03405]
  2. CACMS Outstanding Youth Program [ZZ15-YQ-048]
  3. National Key R&D Program of China [2018YFC1705800]
  4. National Natural Science Foundation of China [82004181]
  5. Joint Sino-German Research Project [GZ1236]
  6. Fundamental Research Funds for Beijing Municipal Science Commission [Z161100002616003]

Ask authors/readers for more resources

The study found that transcutaneous auricular vagus nerve stimulation (taVNS) is as effective as the commonly used antidepressant citalopram in treating major depressive disorder. Furthermore, taVNS showed significantly higher remission rates at week four and week six compared to citalopram.
Objectives: Major depressive disorder (MDD) is one of the most common mental illnesses. This study aims to investigate the effectiveness of transcutaneous auricular vagus nerve stimulation (taVNS) compared with the effectiveness of citalopram, a commonly used antidepressant, in patients with depression. Material and Methods: A total of 107 male and female patients with MDD (55 in the taVNS group and 52 in the citalopram group) were enrolled in a prospective 12-week, single-blind, comparative effectiveness trial. Participants were recruited from the outpatient departments of three hospitals in China. Participants were randomly assigned to either taVNS treatment (eight weeks, twice per day, with an additional four-week follow-up) or citalopram treatment (12 weeks, 40 mg/d). The primary outcome was the 17-item Hamilton Depression Rating Scale (HAM-D-17) measured every two weeks by trained interviewers blinded to the treatment assignment. The secondary end points included the 14-item Hamilton Anxiety Scale and peripheral blood biochemical indexes. Results: The HAM-D-17 scores were reduced in both treatment groups; however, there was no significant group-by-time interaction (95% CI: -0.07 to 0.15, p = 0.79). Nevertheless, we found that taVNS produced a significantly higher remission rate at week four and week six than citalopram. Both treatments were associated with significant changes in the peripheral blood levels of 5-hydroxytryptamine, dopamine, gamma-aminobutyric acid, and noradrenaline, but there was no significant difference between the two groups. Conclusion: taVNS resulted in symptom improvement similar to that of citalopram; thus, taVNS should be considered as a therapeutic option in the multidisciplinary management of MDD. Nevertheless, owing to the design of this study, it cannot be ruled out that the reduction in depression severity in both treatment groups could be a placebo effect.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available